United States — Food and Drug Administration & Viatris

United States — Food and Drug Administration: The FDA granted approval for Gwyn Lo via the 505(b)(2) pathway, adding a new contraceptive option to the market. This action reflects the agency's regulatory role in evaluating drug safety and efficacy.

Viatris: Viatris received FDA approval for Gwyn Lo, a new once-weekly contraceptive patch with low-dose estrogen, expanding its women's health portfolio. The approval is a positive regulatory milestone, though commercial impact depends on launch timing, pricing, and payer coverage.